HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Church & Dwight Delays Expanding VMS Production Capacity As Pandemic-Driven Sales Growth Slows

Executive Summary

Sales of Waterpik oral care devices and Flawless feminine hair-removal, skin and nail care line also slowed during Q3. Those two and vitamin business combined for 6% drag on net sales, finishing flat at $1.32bn.

You may also be interested in...

C&D Powers Into Acne Market Acquiring Hero Cosmetics, Maker Of Top-Selling Mighty Patch

Church & Dwight agrees to buy Hero Cosmetics, maker of acne and skin care patches and topical products, for $630m, adding leading US acne patch brand to its “power brand” lineup. Mighty Patch is among more-than 30 products Hero manufactures and markets.

Church & Dwight Improves On Meeting Demand, But Doesn’t Deliver Better Full-Year Forecast

Lowers full-year forecast for reported sales growth to 4% to 5% from an earlier estimate of 5% to 8% despite improving to 89% on meeting demand during the April-June period from 80% during Q1.

Consumers’ Inflation Fatigue, Recession Fears May Put Health, Beauty Product Price Increases On Hold

Church & Dwight, Perrigo executives' comments at investor conferences could signal OTC drug, supplement and personal care product firms are moving from gauging pandemic impact on supply chains and consumer spending to anticipating shifts in consumer preferences and cost increases caused by inflation with recession appearing more likely every day.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts